These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 33761582)

  • 81. A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review.
    Talukder A; Kalita C; Neog N; Goswami C; Sarma MK; Hazarika I
    Z Naturforsch C J Biosci; 2022 Jul; 77(7-8):351-362. PubMed ID: 35245422
    [TBL] [Abstract][Full Text] [Related]  

  • 82. An overview of vaccine development for COVID-19.
    Shahcheraghi SH; Ayatollahi J; Aljabali AA; Shastri MD; Shukla SD; Chellappan DK; Jha NK; Anand K; Katari NK; Mehta M; Satija S; Dureja H; Mishra V; Almutary AG; Alnuqaydan AM; Charbe N; Prasher P; Gupta G; Dua K; Lotfi M; Bakshi HA; Tambuwala MM
    Ther Deliv; 2021 Mar; 12(3):235-244. PubMed ID: 33624533
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Vaccine nationalism: a predicament in ending the COVID-19 pandemic.
    Lagman JDN
    J Public Health (Oxf); 2021 Jun; 43(2):e375-e376. PubMed ID: 33730161
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Landscape and progress of global COVID-19 vaccine development.
    Huang HY; Wang SH; Tang Y; Sheng W; Zuo CJ; Wu DW; Fang H; Du Q; Li N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3276-3280. PubMed ID: 34254894
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Key steps in our journey to a COVID-19 vaccine program.
    Blyth CC; Flanagan KL; Gibbs RA; Crawford NW; Cheng AC
    Med J Aust; 2021 Apr; 214(6):249-251.e1. PubMed ID: 33745153
    [No Abstract]   [Full Text] [Related]  

  • 86. RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress.
    Rudvan Al LI; Sönmezer MÇ; Ünal S
    Turk J Med Sci; 2021 Dec; 51(SI-1):3246-3252. PubMed ID: 34365779
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vaccine Strategy During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.
    Barnby E; Reynolds M; Gordon J
    NASN Sch Nurse; 2021 Nov; 36(6):316-322. PubMed ID: 34060925
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19.
    Mustajab T; Kwamboka MS; Choi DA; Kang DW; Kim J; Han KR; Han Y; Lee S; Song D; Chwae YJ
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232549
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Tanzania's position on the COVID-19 pandemic.
    Mfinanga SG; Mnyambwa NP; Minja DT; Ntinginya NE; Ngadaya E; Makani J; Makubi AN
    Lancet; 2021 Apr; 397(10284):1542-1543. PubMed ID: 33864748
    [No Abstract]   [Full Text] [Related]  

  • 90. Development of synthetic antigen vaccines for COVID-19.
    Viana Invenção MDC; Melo ARDS; de Macêdo LS; da Costa Neves TSP; de Melo CML; Cordeiro MN; de Aragão Batista MV; de Freitas AC
    Hum Vaccin Immunother; 2021 Nov; 17(11):3855-3870. PubMed ID: 34613880
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Covid-19: Chinese vaccines may need changes to improve efficacy, admits official.
    Dyer O
    BMJ; 2021 Apr; 373():n969. PubMed ID: 33849893
    [No Abstract]   [Full Text] [Related]  

  • 92. Advances in COVID-19 mRNA vaccine development.
    Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist.
    Andrew MK; Schmader KE; Rockwood K; Clarke B; McElhaney JE
    Clin Interv Aging; 2021; 16():731-738. PubMed ID: 33953551
    [TBL] [Abstract][Full Text] [Related]  

  • 94. COVID-19 vaccine and the cold chain implications for global adoption.
    Das MK
    Indian J Public Health; 2021; 65(3):307-310. PubMed ID: 34558497
    [TBL] [Abstract][Full Text] [Related]  

  • 95. COVID-19 in the elderly people and advances in vaccination approaches.
    Dhama K; Patel SK; Natesan S; Vora KS; Iqbal Yatoo M; Tiwari R; Saxena SK; Singh KP; Singh R; Malik YS
    Hum Vaccin Immunother; 2020 Dec; 16(12):2938-2943. PubMed ID: 33270497
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Vaccine trials during a pandemic: potential approaches to ethical dilemmas.
    Alqahtani M; Mallah SI; Stevenson N; Doherty S
    Trials; 2021 Sep; 22(1):628. PubMed ID: 34526086
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Moore S; Hill EM; Dyson L; Tildesley MJ; Keeling MJ
    Nat Med; 2022 Nov; 28(11):2416-2423. PubMed ID: 36302894
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The race to make a COVID-19 vaccine.
    Boseley S
    Lancet; 2021 Sep; 398(10303):832-833. PubMed ID: 34481566
    [No Abstract]   [Full Text] [Related]  

  • 99. Clinical development and approval of COVID-19 vaccines.
    Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
    Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Psychobehavioral Responses and Likelihood of Receiving COVID-19 Vaccines during the Pandemic, Hong Kong.
    Kwok KO; Li KK; Tang A; Tsoi MTF; Chan EYY; Tang JWT; Wong A; Wei WI; Wong SYS
    Emerg Infect Dis; 2021 Jul; 27(7):1802-1810. PubMed ID: 34152948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.